Yeedozencom will hold an online broadcast titled “Yeedo Share” on September 12, at 19:00. Dr. Yu Feifei, Deputy Director of the Medical Department at Yeedozencom, will present on the topic of “Drug-drug Interaction Evaluation Strategies: From In Vitro to Clinical Studies”.

Recently, Suzhou Homesun Pharmaceutical Co., Ltd. (hereinafter referred to as “Homesun Pharmaceutical”), received approval letters from the National Medical Products Administration (NMPA) for their products Levofloxacin Tablets (0.5 g), Amiodarone Hydrochloride Injection (3 mL:150 mg), and Acetylcysteine Solution for Inhalation (3 mL:0.3 g).

On August 21, 2024, Dupert® (Fulzerasib tablets) developed by GenFleet Therapeutics was approved by the National Medical Products Administration (NMPA) for marketing as a treatment of advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior line of systemic therapy, marking it as the first approved KRAS G12C inhibitor in China.